{"extractions": [{"extraction_class": "report_header", "extraction_text": "PROTOCOL NUMBER: CARDIO-HTN-2024-892", "char_interval": {"start_pos": 0, "end_pos": 36}, "alignment_status": "match_exact", "extraction_index": 1, "group_index": 0, "description": null, "attributes": {"section": "Protocol Summary"}}, {"extraction_class": "report_header", "extraction_text": "STUDY TITLE: Phase III Double-Blind Study of Antihypertensive Agent ACE-X47", "char_interval": {"start_pos": 37, "end_pos": 112}, "alignment_status": "match_exact", "extraction_index": 2, "group_index": 1, "description": null, "attributes": {"section": "Protocol Summary"}}, {"extraction_class": "report_header", "extraction_text": "PRINCIPAL INVESTIGATOR: Dr. Michael Rodriguez, MD", "char_interval": {"start_pos": 113, "end_pos": 162}, "alignment_status": "match_exact", "extraction_index": 3, "group_index": 2, "description": null, "attributes": {"section": "Investigator Information"}}, {"extraction_class": "report_header", "extraction_text": "REGULATORY STATUS: FDA IND 67891, EMA CTA 2024-002847-33", "char_interval": {"start_pos": 163, "end_pos": 219}, "alignment_status": "match_exact", "extraction_index": 4, "group_index": 3, "description": null, "attributes": {"section": "Regulatory Status"}}, {"extraction_class": "report_header", "extraction_text": "IRB APPROVAL: Metropolitan Medical Center IRB #2024-1456, Approved August 22, 2024", "char_interval": {"start_pos": 220, "end_pos": 302}, "alignment_status": "match_exact", "extraction_index": 5, "group_index": 4, "description": null, "attributes": {"section": "Approval Information"}}, {"extraction_class": "analysis_body", "extraction_text": "The primary endpoint of systolic blood pressure reduction was achieved with statistical significance.", "char_interval": {"start_pos": 321, "end_pos": 420}, "alignment_status": "match_fuzzy", "extraction_index": 6, "group_index": 5, "description": null, "attributes": {"section": "Efficacy Analysis", "clinical_significance": "significant", "regulatory_impact": "high", "evidence_quality": "strong"}}, {"extraction_class": "analysis_body", "extraction_text": "Mean reduction from baseline was 18.4 mmHg in the treatment group versus 3.2 mmHg in placebo group (p<0.001).", "char_interval": {"start_pos": 421, "end_pos": 530}, "alignment_status": "match_exact", "extraction_index": 7, "group_index": 6, "description": null, "attributes": {"section": "Efficacy Analysis", "clinical_significance": "significant", "regulatory_impact": "high", "evidence_quality": "strong"}}, {"extraction_class": "analysis_body", "extraction_text": "Diastolic blood pressure decreased by 11.7 mmHg versus 1.8 mmHg respectively (p<0.001).", "char_interval": {"start_pos": 531, "end_pos": 618}, "alignment_status": "match_exact", "extraction_index": 8, "group_index": 7, "description": null, "attributes": {"section": "Efficacy Analysis", "clinical_significance": "significant", "regulatory_impact": "medium", "evidence_quality": "strong"}}, {"extraction_class": "analysis_body", "extraction_text": "Response rate, defined as achieving target blood pressure <140/90 mmHg, was 78.3% in active treatment versus 24.1% in placebo group.", "char_interval": {"start_pos": 619, "end_pos": 751}, "alignment_status": "match_exact", "extraction_index": 9, "group_index": 8, "description": null, "attributes": {"section": "Efficacy Analysis", "clinical_significance": "significant", "regulatory_impact": "high", "evidence_quality": "strong"}}, {"extraction_class": "analysis_body", "extraction_text": "Time to blood pressure control was significantly shorter at 4.2 weeks compared to 12.8 weeks.", "char_interval": {"start_pos": 752, "end_pos": 845}, "alignment_status": "match_exact", "extraction_index": 10, "group_index": 9, "description": null, "attributes": {"section": "Efficacy Analysis", "clinical_significance": "significant", "regulatory_impact": "medium", "evidence_quality": "strong"}}, {"extraction_class": "analysis_body", "extraction_text": "Peak plasma concentration was reached at 2.8 hours post-dose.", "char_interval": {"start_pos": 875, "end_pos": 936}, "alignment_status": "match_exact", "extraction_index": 11, "group_index": 10, "description": null, "attributes": {"section": "Pharmacokinetics", "clinical_significance": "normal", "regulatory_impact": "medium", "evidence_quality": "strong"}}, {"extraction_class": "analysis_body", "extraction_text": "Half-life was 14.6 hours, supporting once-daily dosing.", "char_interval": {"start_pos": 937, "end_pos": 992}, "alignment_status": "match_exact", "extraction_index": 12, "group_index": 11, "description": null, "attributes": {"section": "Pharmacokinetics", "clinical_significance": "normal", "regulatory_impact": "medium", "evidence_quality": "strong"}}, {"extraction_class": "analysis_body", "extraction_text": "Steady-state achieved by day 5 with no significant accumulation.", "char_interval": {"start_pos": 993, "end_pos": 1057}, "alignment_status": "match_exact", "extraction_index": 1, "group_index": 0, "description": null, "attributes": {"section": "Pharmacokinetics", "clinical_significance": "normal", "regulatory_impact": "medium", "evidence_quality": "strong"}}, {"extraction_class": "analysis_body", "extraction_text": "Treatment-emergent adverse events occurred in 42% of patients versus 38% placebo.", "char_interval": {"start_pos": 1075, "end_pos": 1156}, "alignment_status": "match_exact", "extraction_index": 2, "group_index": 1, "description": null, "attributes": {"section": "Safety Profile", "clinical_significance": "minor", "regulatory_impact": "medium", "safety_level": "caution"}}, {"extraction_class": "analysis_body", "extraction_text": "Most common events were dizziness (8.1%), headache (6.3%), and fatigue (4.7%).", "char_interval": {"start_pos": 1157, "end_pos": 1235}, "alignment_status": "match_exact", "extraction_index": 3, "group_index": 2, "description": null, "attributes": {"section": "Safety Profile", "clinical_significance": "minor", "regulatory_impact": "medium", "safety_level": "caution"}}, {"extraction_class": "analysis_body", "extraction_text": "No serious drug-related adverse events reported.", "char_interval": {"start_pos": 1236, "end_pos": 1284}, "alignment_status": "match_exact", "extraction_index": 4, "group_index": 3, "description": null, "attributes": {"section": "Safety Profile", "clinical_significance": "normal", "regulatory_impact": "high", "safety_level": "routine"}}, {"extraction_class": "analysis_body", "extraction_text": "Laboratory parameters remained stable throughout the study period.", "char_interval": {"start_pos": 1285, "end_pos": 1351}, "alignment_status": "match_exact", "extraction_index": 5, "group_index": 4, "description": null, "attributes": {"section": "Safety Profile", "clinical_significance": "normal", "regulatory_impact": "medium", "safety_level": "routine"}}, {"extraction_class": "recommendations_section", "extraction_text": "Initiate therapy at 10mg once daily.", "char_interval": {"start_pos": 1377, "end_pos": 1413}, "alignment_status": "match_exact", "extraction_index": 6, "group_index": 5, "description": null, "attributes": {"section": "Dosing", "safety_level": "routine"}}, {"extraction_class": "recommendations_section", "extraction_text": "Titrate to 20mg daily after 2 weeks if blood pressure target not achieved.", "char_interval": {"start_pos": 1414, "end_pos": 1488}, "alignment_status": "match_exact", "extraction_index": 7, "group_index": 6, "description": null, "attributes": {"section": "Dosing", "safety_level": "routine"}}, {"extraction_class": "recommendations_section", "extraction_text": "Maximum recommended dose is 40mg daily.", "char_interval": {"start_pos": 1489, "end_pos": 1528}, "alignment_status": "match_exact", "extraction_index": 8, "group_index": 7, "description": null, "attributes": {"section": "Dosing", "safety_level": "warning"}}, {"extraction_class": "regulatory_footer", "extraction_text": "Study conducted per Good Clinical Practice guidelines and FDA 21 CFR Part 312 requirements.", "char_interval": {"start_pos": 1553, "end_pos": 1644}, "alignment_status": "match_exact", "extraction_index": 9, "group_index": 8, "description": null, "attributes": {}}], "text": "PROTOCOL NUMBER: CARDIO-HTN-2024-892\nSTUDY TITLE: Phase III Double-Blind Study of Antihypertensive Agent ACE-X47\nPRINCIPAL INVESTIGATOR: Dr. Michael Rodriguez, MD\nREGULATORY STATUS: FDA IND 67891, EMA CTA 2024-002847-33\nIRB APPROVAL: Metropolitan Medical Center IRB #2024-1456, Approved August 22, 2024\n\nEFFICACY ANALYSIS:\nPrimary endpoint of systolic blood pressure reduction was achieved with statistical significance. Mean reduction from baseline was 18.4 mmHg in the treatment group versus 3.2 mmHg in placebo group (p<0.001). Diastolic blood pressure decreased by 11.7 mmHg versus 1.8 mmHg respectively (p<0.001). Response rate, defined as achieving target blood pressure <140/90 mmHg, was 78.3% in active treatment versus 24.1% in placebo group. Time to blood pressure control was significantly shorter at 4.2 weeks compared to 12.8 weeks.\n\nPHARMACOKINETIC PARAMETERS:\nPeak plasma concentration was reached at 2.8 hours post-dose. Half-life was 14.6 hours, supporting once-daily dosing. Steady-state achieved by day 5 with no significant accumulation.\n\nSAFETY PROFILE:\nTreatment-emergent adverse events occurred in 42% of patients versus 38% placebo. Most common events were dizziness (8.1%), headache (6.3%), and fatigue (4.7%). No serious drug-related adverse events reported. Laboratory parameters remained stable throughout the study period.\n\nDOSING RECOMMENDATIONS:\nInitiate therapy at 10mg once daily. Titrate to 20mg daily after 2 weeks if blood pressure target not achieved. Maximum recommended dose is 40mg daily.\n\nREGULATORY COMPLIANCE:\nStudy conducted per Good Clinical Practice guidelines and FDA 21 CFR Part 312 requirements.", "document_id": "doc_9bc2020e"}
